Systemic sclerosis-related interstitial lung diseases: diagnosis and treatment approach

1. Makino S. Progressive fibrosing interstitial lung diseases: a new concept and indication of nintedanib. Modern Rheumatology/the Japan Rheumatism Association. 2021;31: 13–19. doi:10.1080/14397595.2020.1826665 Makino S. Progressive fibrosing interstitial lung diseases: a new concept and indication of nintedanib . Modern Rheumatology/the Japan Rheumatism Association . 2021 ; 31 : 13 – 19 . 10.1080/14397595.2020.1826665 Open DOISearch in Google Scholar

2. Gagliardi M, Berg DV, Heylen C-E, Koenig S, Hoton D, Tamirou F, et al. Real-life prevalence of progressive fibrosing interstitial lung diseases. Scientific Reports. 2021;11: 23988. doi:10.1038/s41598-021-03481-8 Gagliardi M Berg DV Heylen C-E Koenig S Hoton D Tamirou F Real-life prevalence of progressive fibrosing interstitial lung diseases . Scientific Reports . 2021 ; 11 : 23988 . 10.1038/s41598-021-03481-8 Open DOISearch in Google Scholar

3. Albera C, Verri G, Sciarrone F, Sitia E, Mangiapia M, Solidoro P. Progressive fibrosing interstitial lung diseases: a current perspective. Biomedicines. 2021;9: 1237. doi:10.3390/biomedicines9091237 Albera C Verri G Sciarrone F Sitia E Mangiapia M Solidoro P. Progressive fibrosing interstitial lung diseases: a current perspective . Biomedicines . 2021 ; 9 : 1237 . 10.3390/biomedicines9091237 Open DOISearch in Google Scholar

4. Althobiani MA, Russell AM, Jacob J, Ranjan Y, Folarin AA, Hurst JR, et al. Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Frontiers in Medicine. 2024;11: 1296890. doi:10.3389/fmed.2024.1296890 Althobiani MA Russell AM Jacob J Ranjan Y Folarin AA Hurst JR Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment . Frontiers in Medicine . 2024 ; 11 : 1296890 . 10.3389/fmed.2024.1296890 Open DOISearch in Google Scholar

5. Antoine MH, Mlika M. Interstitial Lung Disease [Internet]. Bethesda (MD): StatPearls; 2023 [updated 2023; accessed 2024 July 18]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541084 Antoine MH Mlika M. Interstitial Lung Disease [Internet] . Bethesda (MD) : StatPearls ; 2023 [updated 2023; accessed 2024 July 18 ]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541084 Search in Google Scholar

6. Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respiratory Research. 2019;20: 13. doi:10.1186/s12931-019-0980-7 Cottin V Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD) . Respiratory Research . 2019 ; 20 : 13 . 10.1186/s12931-019-0980-7 Open DOISearch in Google Scholar

7. Vonk MC, Walker UA, Volkmann ER, Kreuter M, Johnson SR, Allanore Y. Natural variability in the disease course of SSc-ILD: implications for treatment. European Respiratory Review. 2021;30: 200340. doi:10.1183/16000617.0340-2020 Vonk MC Walker UA Volkmann ER Kreuter M Johnson SR Allanore Y. Natural variability in the disease course of SSc-ILD: implications for treatment . European Respiratory Review . 2021 ; 30 : 200340 . 10.1183/16000617.0340-2020 Open DOISearch in Google Scholar

8. Qiu M, Nian X, Pang L, Yu P, Zou S. Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: a systematic review and meta-analysis. International Journal of Rheumatic Diseases. 2021;24: 1449–1459. doi:10.1111/1756-185X.14206 Qiu M Nian X Pang L Yu P Zou S. Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: a systematic review and meta-analysis . International Journal of Rheumatic Diseases . 2021 ; 24 : 1449 – 1459 . 10.1111/1756-185X.14206 Open DOISearch in Google Scholar

9. Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. American Journal of Respiratory and Critical Care Medicine. 2020;201: 650–660. doi:10.1164/rccm.201903-0563CI Khanna D Tashkin DP Denton CP Renzoni EA Desai SR Varga J. Etiology, risk factors and biomarkers in systemic sclerosis with interstitial lung disease . American Journal of Respiratory and Critical Care Medicine . 2020 ; 201 : 650 – 660 . 10.1164/rccm.201903-0563CI Open DOISearch in Google Scholar

10. Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. European Respiratory Journal. 2020;55: 1902026. doi:10.1183/13993003.02026-2019 Distler O Assassi S Cottin V Cutolo M Danoff SK Denton CP Predictors of progression in systemic sclerosis patients with interstitial lung disease . European Respiratory Journal . 2020 ; 55 : 1902026 . 10.1183/13993003.02026-2019 Open DOISearch in Google Scholar

11. Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clinical Epidemiology. 2019;11: 257–273. doi:10.2147/CLEP.S191418 Bergamasco A Hartmann N Wallace L Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease . Clinical Epidemiology . 2019 ; 11 : 257 – 273 . 10.2147/CLEP.S191418 Open DOISearch in Google Scholar

12. Fan Y, Bender S, Shi W, Zoz D. Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States. Journal of Managed Care & Specialty Pharmacy. 2020;26: 1539–1547. doi:10.18553/jmcp.2020.20136 Fan Y Bender S Shi W Zoz D. Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States . Journal of Managed Care & Specialty Pharmacy . 2020 ; 26 : 1539 – 1547 . 10.18553/jmcp.2020.20136 Open DOISearch in Google Scholar

13. Khanna D, Distler O, Cottin V, Brown KK, Chung L, Goldin JG, et al. Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. Journal of Scleroderma and Related Disorders. 2022;7: 168–178. doi:10.1177/23971983211064463 Khanna D Distler O Cottin V Brown KK Chung L Goldin JG Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography . Journal of Scleroderma and Related Disorders . 2022 ; 7 : 168 – 178 . 10.1177/23971983211064463 Open DOISearch in Google Scholar

14. Hoffmann-Vold AM, Fretheim H, Halse AK, Seip M, Bitter H, Wallenius M, et al. Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. American Journal of Respiratory and Critical Care Medicine. 2019;200: 1258–1266. doi:10.1164/rccm.201903-0486OC Hoffmann-Vold AM Fretheim H Halse AK Seip M Bitter H Wallenius M Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort . American Journal of Respiratory and Critical Care Medicine . 2019 ; 200 : 1258 – 1266 . 10.1164/rccm.201903-0486OC Open DOISearch in Google Scholar

15. Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Annals of the Rheumatic Diseases. 2021;80: 219–227. doi:10.1136/annrheumdis-2020-217455 Hoffmann-Vold AM Allanore Y Alves M Brunborg C Airó P Ananieva LP Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database . Annals of the Rheumatic Diseases . 2021 ; 80 : 219 – 227 . 10.1136/annrheumdis-2020-217455 Open DOISearch in Google Scholar

16. Hoffmann-Vold AM, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. The Lancet. Rheumatology. 2020;2: e71–e83. doi:10.1016/S2665-9913(19)30144-4 Hoffmann-Vold AM Maher TM Philpot EE Ashrafzadeh A Barake R Barsotti S The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements . The Lancet. Rheumatology . 2020 ; 2 : e71 – e83 . 10.1016/S2665-9913(19)30144-4 Open DOISearch in Google Scholar

17. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis–associated interstitial lung disease. New England Journal of Medicine. 2019;380: 2518–2528. doi:10.1056/NEJMoa1903076 Distler O Highland KB Gahlemann M Azuma A Fischer A Mayes MD Nintedanib for systemic sclerosis–associated interstitial lung disease . New England Journal of Medicine . 2019 ; 380 : 2518 - 2528 . 10.1056/NEJMoa1903076 Open DOISearch in Google Scholar

18. Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Annals of the Rheumatic Diseases. 2020;79: 1478–1484. doi:10.1136/annrheumdis-2020-217331 Seibold JR Maher TM Highland KB Assassi S Azuma A Hummers LK Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial . Annals of the Rheumatic Diseases . 2020 ; 79 : 1478 – 1484 . 10.1136/annrheumdis-2020-217331 Open DOISearch in Google Scholar

19. Bendstrup E, Wuyts W, Alfaro T, Chaudhuri N, Cornelissen R, Kreuter M, et al. Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events. Respiration; International Review of Thoracic Diseases. 2019;97: 173–184. doi:10.1159/000495046 Bendstrup E Wuyts W Alfaro T Chaudhuri N Cornelissen R Kreuter M Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events . Respiration; International Review of Thoracic Diseases . 2019 ; 97 : 173 – 184 . 10.1159/000495046 Open DOISearch in Google Scholar

20. Proesmans VLJ, Drent M, Elfferich MDP, Wijnen PAHM, Jessurun NT, Bast A. Self-reported gastrointestinal side effects of antifibrotic drugs in Dutch idiopathic pulmonary fibrosis patients. Lung. 2019;197: 551–558. doi:10.1007/s00408-019-00260-1 Proesmans VLJ Drent M Elfferich MDP Wijnen PAHM Jessurun NT Bast A. Self-reported gastrointestinal side effects of antifibrotic drugs in Dutch idiopathic pulmonary fibrosis patients . Lung . 2019 ; 197 : 551 – 558 . 10.1007/s00408-019-00260-1 Open DOISearch in Google Scholar

21. Cui Y, Zhang M, Leng C, Blokzijl T, Jansen BH, Dijkstra G, et al. Pirfenidone inhibits cell proliferation and collagen I production of primary human intestinal fibroblasts. Cells. 2020;9: 775. doi:10.3390/cells9030775 Cui Y Zhang M Leng C Blokzijl T Jansen BH Dijkstra G Pirfenidone inhibits cell proliferation and collagen I production of primary human intestinal fibroblasts . Cells . 2020 ; 9 : 775 . 10.3390/cells9030775 Open DOISearch in Google Scholar

22. Roofeh D, Distler O, Allanore Y, Denton CP, Khanna D. Treatment of systemic sclerosis–associated interstitial lung disease: lessons from clinical trials. Journal of Scleroderma and Related Disorders. 2020;5: 61–71. doi:10.1177/2397198320903208 Roofeh D Distler O Allanore Y Denton CP Khanna D. Treatment of systemic sclerosis–associated interstitial lung disease: lessons from clinical trials . Journal of Scleroderma and Related Disorders . 2020 ; 5 : 61 – 71 . 10.1177/2397198320903208 Open DOISearch in Google Scholar

23. Roofeh D, Jaafar S, Vummidi D, Khanna D. Management of systemic sclerosis-associated interstitial lung disease. Current Opinion in Rheumatology. 2019;31: 241–249. doi:10.1097/BOR.0000000000000592 Roofeh D Jaafar S Vummidi D Khanna D. Management of systemic sclerosis-associated interstitial lung disease . Current Opinion in Rheumatology . 2019 ; 31 : 241 - 249 . 10.1097/BOR.0000000000000592 Open DOISearch in Google Scholar